| Date | Title | | | | 12/13/2012 | Meridian Bioscience Successfully Completes Beta Trials for Two New illumigene® Tests| CINCINNATI--(BUSINESS WIRE)--Dec. 13, 2012--
Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that it has
successfully completed beta trials for two new illumigene molecular
amplification tests. These assays are designed to
specifically detect the DNA of Chlamydia trachomatis and Neisseria
gonorrhoeae, respectively, from both swab and urine samples.
For the first time, these two new assays will also incorporate Meridian
Bioscience’s new... |
| |  | | 12/4/2012 | Meridian Bioscience, Inc. Declares Regular Quarterly Dividend and Accelerates Payment Date to December 24, 2012| CINCINNATI--(BUSINESS WIRE)--Dec. 4, 2012--
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) announced
that its Board of Directors today declared an accelerated cash dividend
of $0.19 per share payable on December 24, 2012 to shareholders of
record on December 14, 2012. The declaration and payment of this cash
dividend is in lieu of the regular quarterly cash dividend that would
have normally been paid in February 2013.
The a... |
| | | | 11/28/2012 | SensiFAST™ Genotyping Kit Exceed the Limit| CINCINNATI--(BUSINESS WIRE)--Nov. 28, 2012--
Bioline, The PCR Company, a wholly-owned subsidiary of Meridian
Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the worldwide
release of SensiFAST Genotyping Kit, which has been specifically
developed for the important field of genotyping.
Bioline’s SensiFAST Genotyping Kit has been developed for fast, precise,
and highly reproducible genotyping of sequence variants, including loci
with... |
| | | | 11/8/2012 | Meridian Bioscience Reports Fourth Quarter and Full-Year 2012 Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2013 Guidance| CINCINNATI--(BUSINESS WIRE)--Nov. 8, 2012--
Meridian Bioscience, Inc.:
GENERAL HIGHLIGHTS
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today:
reported record fourth quarter and full-year fiscal 2012 net sales of
$43.7 million and $173.5 million, respectively, increases of 6% and
9%, respectively, from the same periods of the prior fiscal year;
reported record fourth quarter ... |
| | | | 9/17/2012 | Meridian Bioscience Receives FDA Clearance for New Molecular Test: illumigene® Group A Strep| CINCINNATI--(BUSINESS WIRE)--Sep. 17, 2012--
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today
announced that it has received FDA clearance for a new molecular
diagnostic test for Group A Streptococcus on the illumigene®
platform.
Group A Streptococcus is a bacterium commonly found in the human
throat or on skin and causes a wide variety of diseases in humans, the
most common being acute pharyngitis or strep throat. Grou... |
| | | | 8/28/2012 | Meridian Bioscience Provides Sales and Earnings Guidance for Fiscal 2013 and Reaffirms Fiscal 2012 Guidance| CINCINNATI--(BUSINESS WIRE)--Aug. 28, 2012--
Meridian Bioscience, Inc. (NASDAQ: VIVO) today provided the financial
community with guidance regarding the Company’s fiscal 2013 sales and
earnings estimates. Based on the Company’s business planning and
budgeting activities for the fiscal year ending September 30, 2013,
management expects net sales to be in the range of $190 to $195 million
and per share diluted earnings to be between $0.86 and $0.91. Th... |
| | | | 7/26/2012 | Meridian Bioscience Reports Third Quarter and Nine Months Operating Results, Declares Regular Cash Dividend, and Revises Fiscal 2012 Guidance| CINCINNATI--(BUSINESS WIRE)--Jul. 26, 2012--
Meridian Bioscience, Inc. (NASDAQ: VIVO):
GENERAL HIGHLIGHTS
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today:
reported fiscal 2012 third quarter and nine months net sales of $42.1
million and $129.8 million, respectively, increases of 5% and 10%,
respectively, from the same periods of the prior fiscal year;
reported third quart... |
| | | | 7/17/2012 | Meridian Bioscience, Inc. to Release Fiscal 2012 Third Quarter and Nine Months Operating Results on July 26| CINCINNATI--(BUSINESS WIRE)--Jul. 17, 2012--
Meridian Bioscience, Inc. (NASDAQ: VIVO) has scheduled the release of
its fiscal 2012 third quarter and nine months operating results on
Thursday, July 26 at approximately 7:15 a.m. (Eastern).
Meridian Bioscience is a fully integrated life science company that
manufactures, markets and distributes a broad range of innovative
diagnostic test kits, purified reagents and related products and offers
... |
| | | | 4/26/2012 | Meridian Bioscience Reports Record Second Quarter and First Six
Months Operating Results, Declares Regular Cash Dividend, and Reaffirms
Fiscal 2012 Guidance| CINCINNATI, Apr 26, 2012 (BUSINESS WIRE) --Meridian Bioscience, Inc. (NASDAQ: VIVO):
GENERAL HIGHLIGHTS
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today:
reported record fiscal 2012 second quarter and six months net sales of
$47.4 million and $87.7 million, respectively, increases of 16% and
12%, respectively, from the same periods of the prior fiscal year;
reported record second quarter operating income ... |
| | | | 4/12/2012 | Meridian Bioscience Awarded New Agreement with Premier Healthcare
Alliance for Molecular Diagnostic Tests and Instruments for C.
difficile and Group B Streptococcus| CINCINNATI, Apr 12, 2012 (BUSINESS WIRE) --Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced it has signed a
new group purchasing agreement with the Premier healthcare alliance to
offer illumigene(R) C. difficile
and illumigene Group B Streptococcus to its members
at specially negotiated pricing. Premier serves more than 2,500 U.S.
hospitals and 81,000-plus other healthcare sites. This agreement allows
Premier alliance facilities to implemen... |
| | | | 4/12/2012 | Meridian Bioscience, Inc. to Release Fiscal 2012 Second Quarter
Financial Results on April 26| CINCINNATI, Apr 12, 2012 (BUSINESS WIRE) --Meridian Bioscience, Inc. (NASDAQ: VIVO) has scheduled the release of
its 2012 second quarter financial results for Thursday, April 26 at
approximately 7:45 a.m. (Eastern).
ABOUT MERIDIAN BIOSCIENCE, INC.
Meridian is a fully integrated life science company that manufactures,
markets and distributes a broad range of innovative diagnostic test
kits, purified reagents and related products and offers
biopharmace... |
| | | | 3/21/2012 | Bioline Receives Clearance from TGA for the Commercialization in
Australia of the New Molecular Test illumigene(R)
Group B Streptococcus| CINCINNATI, Mar 21, 2012 (BUSINESS WIRE) --Bioline, The PCR Company, a wholly-owned subsidiary of Meridian
Bioscience, Inc. (NASDAQ:VIVO), today announced that it has received
clearance from the Therapeutic Goods Administration (TGA) for its illumigene
Group B Streptococcus (GBS) test, the newest molecular product on
the illumigene platform. The approval in Australia
for the commercialization of illumigene GBS, comes on the
heels of the recent FDA ... |
| | | | 3/21/2012 | Bioline Receives Clearance from TGA for the Commercialization in Australia of the New Molecular Test illumigene® Group B Streptococcus| CINCINNATI--(BUSINESS WIRE)--Mar. 21, 2012--
Bioline, The PCR Company, a wholly-owned subsidiary of Meridian
Bioscience, Inc. (NASDAQ:VIVO), today announced that it has received
clearance from the Therapeutic Goods Administration (TGA) for its illumigene
Group B Streptococcus (GBS) test, the newest molecular product on
the illumigene platform. The approval in Australia
for the commercialization of illumigene GBS, comes on the
heels of the rece... |
| | | | 3/20/2012 | Bioline Celebrates 20 Years of Service to Life Science| CINCINNATI--(BUSINESS WIRE)--Mar. 20, 2012--
Bioline, The PCR Company, a wholly-owned subsidiary of Meridian
Bioscience, Inc. (NASDAQ:VIVO), was founded in London, UK in 1992 by
Marco Calzavara, President of Meridian Bioscience Europe. Bioline is a
leading manufacturer and distributor of PCR enzymes and molecular
biology reagents providing complete solutions to researchers in
universities, major research institutions, hospitals, biotech and
ph... |
| | | | 2/27/2012 | Meridian Bioscience Receives FDA Clearance for New Legionella Test| CINCINNATI--(BUSINESS WIRE)--Feb. 27, 2012--
Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that it has
received FDA clearance from the U.S. Food and Drug Administration (FDA)
for TRU Legionella™, a new rapid assay for detection of legionellosis.
TRU Legionella is a rapid lateral flow device that provides optimized
detection of Legionella pneumophila serogroup 1 that is most
commonly associated with Legionnaire’s disease. Suspected infectio... |
| | | | 2/16/2012 | Bioline Introduces New SensiFAST™ HRM Kit for Gene Mutations and SNP Analysis| CINCINNATI--(BUSINESS WIRE)--Feb. 16, 2012--
Bioline, The PCR Company, a wholly-owned subsidiary of Meridian
Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the latest addition
to its SensiFAST family real-time PCR products.
SensiFAST HRM Kit facilitates High Resolution Melt (HRM) curve analysis,
enabling amplification and discrimination of even the most challenging
sequence differences (such as class 4 SNPs) without sequence preference.... |
| | | | 1/25/2012 | Meridian Bioscience Reports First Quarter 2012 Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2012 Guidance| CINCINNATI--(BUSINESS WIRE)--Jan. 25, 2012-- Meridian Bioscience, Inc. (NASDAQ: VIVO):
GENERAL HIGHLIGHTS
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today:
reported first quarter net sales of $40.3 million, an increase of 8% from the same period of the prior fiscal year;
reported first quarter operating income of $9.8 million, an increase of 8% over the same period of the prior fiscal year;
reported first quarter net earnings of $6.6 million, or $0.16 per diluted shar... |
|  | | | 1/18/2012 | Bioline Introduces HyperPAGE II Broad Range Prestained Protein Marker| CINCINNATI--(BUSINESS WIRE)--Jan. 18, 2012--
Bioline, The PCR Company, a wholly-owned subsidiary of Meridian
Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the latest addition
to its HyperPAGE range of prestained molecular weight protein markers.
HyperPAGE II contains 9 highly purified protein bands from 10 to 250kDa
prestained with different fluorescence dyes to facilitate easy
identification and orientation whether performing protein
... |
| | |
|
